|
|
|
|
Vol. 15, Issue 1, 189-196, January 2004
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||



* Department of Molecular and Cellular Biology, University of Arizona, Tucson, Arizona 85721;
Departments of Pharmacology and Cell Biology, Skirball Institute of Biomolecular Medicine, New York University School of Medicine, New York, New York 10016
Submitted August 19, 2003;
Revised September 14, 2003;
Accepted September 24, 2003
Monitoring Editor: Howard Riezman
| ABSTRACT |
|---|
|
|
|---|
| INTRODUCTION |
|---|
|
|
|---|
Several myotubularins specifically dephosphorylate the 3'-phosphate of phosphoinositide 3-phosphate [PI(3)P] (Blondeau et al., 2000
; Taylor et al., 2000
; Walker et al., 2001
; Zhao et al., 2001
; Berger et al., 2002
; Schaletzky et al., 2003
), and some have been shown to also act on Phosphatidylinositol 3,5-bisphosphate (Walker et al., 2001
; Schaletzky et al., 2003
). Although, the overexpression of human MTMR3 results in enlarged vacuoles in Saccharomyces cerevisiae (Walker et al., 2001
), and the overexpression of human MTM1, MTMR2, or MTMR3 results in enlarged vacuoles in Schizosaccharomyces pombe (Blondeau et al., 2000
; Laporte et al., 2002b
), no actual defect in uptake has been reported in these cells. Furthermore, overexpression of MTM1 in mammalian cells does not noticeably affect vesicular trafficking (Laporte et al., 2002a
). Despite this indirect evidence in support of myotubularin function in membrane traffic, no defect in a specific cellular process has so far been identified in cells lacking an endogenous myotubularin.
By screening for mutants unable to internalize green fluorescent protein (GFP) secreted into the body cavity, we previously identified mutations in 14 cup (coelomocyte up-take defective) genes that disrupt endocytosis by Caenorhabditis elegans coelomocytes, scavenger cells with extremely high endocytic activity (Fares and Greenwald, 2001a
). We describe here the molecular identification of CUP-6 and CUP-10 as two of the six myotubularins found in worms (Laporte et al., 2001
; Wishart et al., 2001
). We also demonstrate a function for these two proteins in an ARF-6- and RME-1-mediated endocytic pathway.
| MATERIALS AND METHODS |
|---|
|
|
|---|
Molecular Methods
Standard methods were used for the manipulation of recombinant DNA (Sambrook et al., 1989
). All enzymes were from New England Biolabs (Beverly, MA), unless otherwise indicated. Site-directed mutagenesis of MTM-6 was done using QuikChange site-directed mutagenesis (Stratagene, La Jolla, CA).
cDNA Sequencing
yk clones (Kohara, personal communication) corresponding to MTM-6 and MTM-9 cDNAs were sequenced in their entirety. The 5' ends of the MTM-6 and MTM-9 mRNAs were determined using 5' rapid amplification of cDNA ends (Roche Diagnostics, Indianapolis, IN).
Plasmids
All DNA constructs were cloned in front of a coelomocyte-specific promoter (Fares and Greenwald, 2001b
). GFP(S65T) (Chalfie et al., 1994
) or mRFP1 (Campbell et al., 2002
), a monomeric form of DsRed, was used for making all fusion proteins; these markers were introduced at the N terminus of RME-1, or at the C terminus of MTM-6, MTM-9, ARF-6, and 2 x FYVE(Hrs). Y116A8C.12 is the C. elegans ARF-6 (Fares, unpublished data). MTM-6, MTM-9, and RME-1 fusion proteins rescued their corresponding mutants. Endocytosis was normal in coelomocytes expressing ARF-6 (for which no mutation exists) and 2 x FYVE(Hrs) fusion proteins. Details of plasmid constructions are available upon request.
Immunoprecipitation
GFP-MTM-6A and Flg-MTM-9 were transfected into human 293 tissue culture cells either alone or together. Total cell lysate (250 mg) was subjected to immunoprecipitation with antibodies against GFP or Flg. The immunoprecipitates were washed three times with radioimmunoprecipitation assay buffer (50 mM Tris-HCl, pH 7.2, 1% Triton X-100, 1% sodium deoxycholate, 0.1% SDS, 0.15 M NaCl, 1% Trasylol), separated by SDS gel electrophoresis (10%), and after transfer to nitrocellulose, Western blotted with antibodies to either GFP or Flg. Total cell lysates (50 µg) were run as a control to show equal levels of protein expression in the transfected cells.
Bovine Serum Albumin-Rhodamine (BSA-Rhod) Endocytosis As described previously (Fares and Greenwald, 2001b
; Zhang et al., 2001
), BSA-Rhod (Sigma-Aldrich, St. Louis, MO) dissolved at 1 mg/ml in water was injected into the pseudocoelom of young adult hermaphrodites at 20°C. At the indicated times, the worms were mounted in a drop of ice-cold 1% formaldehyde, and slides were kept on ice until viewing.
Microscopy
Worms were fixed in 1% formaldehyde. Deconvolution images were recorded as digital images (with Z-series containing 0.15-µm sections) by using a Series 300 charge-coupled device camera (Photometrics, Tucson, AZ) and deconvolved using DeltaVision software (Applied Precision, Issaquah, WA). Confocal images were taken with a Nikon PCM 2000, by using HeNe 543 excitation for the red dye and argon 488 for the green dye.
Accession Numbers
Accession numbers were MTM-6A (AY313177
[GenBank]
), MTM-6B (AY313179
[GenBank]
), and MTM-9 (AY313178
[GenBank]
).
Supplemental Material
Figures showing the gene structures of mtm-6 and mtm-9 are available on the Molecular Biology of the Cell Web site.
| RESULTS |
|---|
|
|
|---|
|
Specific effects of cup-6 and cup-10 mutations on phosphoinositides indicate functional conservation of C. elegans and mammalian myotubularins. Direct visualization of intracellular PI(3)P by using a GFP-tagged, PI(3)P reporter 2 x FYVE(Hrs)::GFP (Gillooly et al., 2000
) showed that both genes are required for PI(3)P localization in vivo (Figure 1). Thus, mutations in cup-6 and in cup-10, but not in other members of a large collection of cup mutants (Fares and Greenwald, 2001a
), caused severe disruption of the PI(3)P staining pattern in vivo (Figure 1; our unpublished data). Given the strong conservation of sequence (Laporte et al., 2001
) and function, we renamed cup-6 as mtm-6 and cup-10 as mtm-9 to conform to both the mammalian and the worm gene nomenclature.
Defective Uptake of Fluid by the Coelomocytes of mtm-6 and mtm-9 Mutants
We determined that mtm-6(ar513) and mtm-9(ar479) coelomocytes were unable to endocytose BSA-Rhod introduced into the body cavity (Figure 2). There are two main advantages of using BSA-Rhod instead of GFP expressed from the pmyo-3::ssGFP transgene for a detailed examination of the endocytic pathway in coelomocytes: 1) we can inject the BSA-Rhod at a higher concentration, thus allowing us to monitor early events in endocytosis; and 2) whereas the GFP is degraded in late endosomes and lysosomes, the rhodamine moiety in BSA-Rhod is not affected, thus allowing us to visualize these compartments.
|
We injected the BSA-Rhod into the body cavity of worms and monitored its uptake by coelomocytes expressing the endosomal marker RME-8::GFP (Zhang et al., 2001
). RME-8::GFP labels endosomes, but not lysosomes in coelomocytes. In a wild-type cell, the BSA-Rhod occurs in RME-8::GFPlabeled compartments by 5 min after its injection into the body cavity. At this time, some of the BSA-Rhod occurs as concentrations, presumed to be nascent lysosomes, budding from these RME-8::GFPlabeled compartments (Fares and Greenwald, 2001b
; Zhang et al., 2001
; Figure 2, large arrow). By 60 min, the BSA-Rhod is concentrated in lysosomes that are not labeled by RME-8::GFP, and remains there for the duration of the experiment (small arrows in Figure 2). In contrast, no BSA-Rhod is seen in mtm-6(ar513) and mtm-9(ar479) coelomocytes by the 5-min and 60-min time point. Indeed, even after 24 h of incubation in BSA-Rhod, relatively small amounts of the BSA-Rhod are taken up by these cells (Figure 2, arrowhead).
This indicates that the rate of endocytosis in mtm-6(ar513) and mtm-9(ar479) coelomocytes is sharply reduced, very likely at an early step in the pathway. Also note that the RME-8::GFP staining pattern in mtm-6 and mtm-9 worms seems more disorganized than in wild-type cells (Figure 2).
Functional Domains of MTM-6
Molecular analysis revealed that mtm-6 encodes two isoforms, MTM-6A that is sufficient to rescue the endocytic defect of mtm-6(ar513) worms (Figure 3), and MTM-6B, which contains additional amino acids at the amino terminus with no obvious motifs (see Supplemental Material). In contrast to MTM-6A::GFP (see below), we could not detect MTM-6B::GFP when overexpressed in coelomocytes, suggesting that it is unstable, nor did it rescue the endocytic defect of mtm-6(ar513) worms or disrupt endocytosis in a wild-type cell (our unpublished data). Furthermore, the absence of MTM-6B does not have an obvious effect on coelomocyte endocytosis because simply expressing MTM-6A rescues the coelomocyte endocytosis defect of mtm-6 mutations that cannot make either form of the protein. Further analysis was therefore done using MTM-6A. mtm-9 encodes a predicted protein that lacks key residues required for phosphatase activity (Figure 3; Supplemental Material).
|
The phosphatase domain of MTM-6 is essential for its in vivo function. This is supported by two lines of evidence: first, mtm-6(ar515), a mutation with a phenotype as severe as an mtm-6 null, contains an amino acid substitution of a conserved aspartic acid residue required by the myotubularin to bind to PIs (Wishart et al., 2001
; Figure 3). Second, transgenic expression of a substrate-trapping mutant (Flint et al., 1997
; Blondeau et al., 2000
; Laporte et al., 2002a
), MTM-6(C335S), causes dominant inhibition of endocytosis (Figure 4).
|
Analysis of specific deletion mutants suggests that the FYVE domain of MTM-6A is required for MTM-6 to maintain its membrane localization. Overexpression of either MTM-6A::GFP or MTM-6A
FYVE::GFP (fusion protein completely lacking the FYVE domain) rescues the endocytosis defect of mtm-6, indicating that, at least under these conditions, the FYVE domain is not required by MTM-6 for its targeting to membranes or for its activity (Figure 4). However, in contrast to MTM-6A(C335S), MTM-6A(C335S)
FYVE did not interfere with coelomocyte endocytosis (Figure 4), indicating that the FYVE domain increases the avidity rather than the affinity of MTM-6A to specific membranes.
Subcellular Localization of MTM-6A and MTM-9
Both MTM-6A::GFP and MTM-6A
FYVE::GFP are largely cytosolic, with some membrane localization (Figure 5A, a and e). In agreement with other myotubularin substrate-trapping mutants (Flint et al., 1997
; Blondeau et al., 2000
; Laporte et al., 2002a
), MTM-6A(C335S)::GFP shows a punctate staining pattern and localizes to the plasma membrane and to compartments close to the plasma membrane in coelomocytes (Figure 5A, b). This membrane association does not require the presence of MTM-9 because it remains unchanged in mtm-9(ar479) worms (Figure 5A, c). In contrast, and in support of its inability to give a dominant negative phenotype, MTM-6A(C335S)
FYVE::GFP is mostly cytoplasmic (Figure 5A, f).
|
Like, MTM-6, the phosphatase-inactive MTM-9 protein is also predominantly localized to the coelomocyte cytoplasm, although as for MTM-6, a functional MTM-9::GFP fusion protein reveals some membrane association (Figure 5A, g).
Physical Association of MTM-6A and MTM-9
Given previous reports of physical interactions between other catalytically active and inactive forms of human and mouse MTM proteins (Kim et al., 2003
; Mochizuki and Majerus, 2003
; Nandurkar et al., 2003
), and the requirement for both MTM-6 and MTM-9 for coelomocyte endocytosis, we thought it possible that MTM-9 could interact with MTM-6A to regulate its activity. Expression of the membrane-associated MTM-6A(C335S) mutant protein increased membrane association of MTM-9, providing in vivo evidence that MTM-6A localization or activity regulates MTM-9 localization (Figure 5A, h).
This regulation of MTM-9 by MTM-6 may be direct, because we determined that MTM-6A and MTM-9 physically associate and/or are part of the same complex. GFP-MTM-6A and Flg-MTM-9 were expressed in human 293 cells either alone, or together, and the ability of the two proteins to coimmunoprecipitate was determined. We found that MTM-6A and MTM-9 coimmunoprecipitated using antibodies to either GFP or Flg (Figure 5B, lanes 3 and 6). The coimmunoprecipitation was specific because it only occurred when both proteins were expressed in the cells (Figure 5B, lanes 4 and 5).
The above-mentioned observations, taken together, provide strong evidence for functional interactions between the catalytically active and inactive forms of MTM proteins in regulating fluid phase endocytosis by coelomocytes, probably through endocytic organelles visualized using the substrate-trapping MTM-6A(C335S)::GFP fusion protein.
Association of MTM-6 with an ARF-6/RME-1 Endocytic Pathway
To better characterize the MTM-6 and MTM-9 endocytic pathway, we further examined the identity of the MTM-6A(C335S)::GFP labeled membranes. Adenosine diphosphate-ribosylation factor 6 (Arf6) is required in some mammalian tissues for nonclathrin-dependent forms of membrane traffic (Naslavsky et al., 2003
). C. elegans ARF-6 is strongly expressed in coelomocytes (our unpublished data) and gives a pattern of localization similar to MTM-6A(C335S)::GFP (Figure 6). Indeed, MTM-6A(C335S)::GFP and ARF-6::mRFP1 show significant colocalization in coelomocytes (Figure 6). Consistent with a function of MTM-6 in PI(3)P metabolism, 2 x FYVE::GFP and ARF-6::mRFP1 also partially colocalize (Figure 6). Furthermore, using deconvolution microscopy to better visualize membrane-associated protein, we find that MTM-9::GFP and ARF-6::mRFP1 significantly colocalize in coelomocytes (our unpublished data).
|
These studies indicate that MTM-6/9-proteins function in a specialized endocytic pathway that involves Arf6. We therefore analyzed other components of the Arf6 pathway in C. elegans. Rme1/Ehd1/Pincher is an epsin homology domain-containing protein that is required for endocytosis or endocytic trafficking in some mammalian cells (Lin et al., 2001
), including the Arf6 pathway in some cell types (Caplan et al., 2002
). RME-1 is the C. elegans homolog of Ehd1 (Grant et al., 2001
) and is required for endocytosis by coelomocytes (Fares and Greenwald, 2001a
; Grant et al., 2001
). Indeed, like their mammalian counterparts (Caplan et al., 2002
), ARF-6::GFP and mRFP1::RME-1 show extensive colocalization in coelomocytes (Figure 6). Consistent with the above results, MTM-6A(C335S)::GFP and mRFP1::RME-1 largely colocalize in coelomocytes (Figure 6). This colocalization is functionally significant because the membrane association of MTM-6A(C335S)::GFP is severely disrupted in rme-1(b1045) mutant worms (Figure 5A, d).
| DISCUSSION |
|---|
|
|
|---|
The identification of mutations in two myotubularins in an unbiased screen for endocytosis mutants strongly argues that a primary role of myotubularins is to regulate endocytosis. Indeed, RNAi analysis suggests that in addition to MTM-6 and MTM-9, worm MTM-1 and MTM-3 are also required for endocytosis by coelomocytes (Xue et al., 2003
). This indicates that the myotubularins have largely nonoverlapping functions in regulating this process, perhaps by regulating PI levels at distinct membranes. This is in agreement with previous studies on human MTM1 and MTMR2 (Laporte et al., 2002b
).
At which step(s) of the coelomocyte endocytic pathway are MTM-6 and MTM-9 required? When we monitored endocytosis in coelomocytes after injecting BSA-Rhod into the body cavity of worms, we saw little/no uptake of the dye in mtm-6 and mtm-9 coelomocytes. The simplest interpretation of these data is that MTM-6 and MTM-9 are required very early in the endocytic pathway in coelomocytes. We favor this model because it is consistent with the colocalization of the proteins with ARF-6 and RME-1 close to and on the plasma membrane. Indeed, in mammalian cells ARF-6 is required at the plasma membrane and in specialized early endosomes (Naslavsky et al., 2003
), whereas a mammalian homolog of RME-1 localizes to cell surface ruffles (Shao et al., 2002
). MTM-6 and MTM-9 could also be required in later endocytic compartments by regulating the levels and/or localization of other essential PI-phosphates directly, or indirectly because PI(3)P is a substrate for making other PI-phosphates. This is consistent with our observation that the RME-8labeled compartments seem more disorganized in mtm-6 and mtm-9 coelomocytes than in wild-type cells. Note that we could detect very little colocalization between RME-8, and ARF-6, RME-1, or CUP-6(C335S) (Fares, unpublished data), indicating that RME-8 localizes to distinct endocytic compartments.
We had previously shown that reducing mtm-6 levels in the intestine results in the appearance of PI(3)P at the apical membrane rather than on internal vesicles (Xue et al., 2003
). This indicates that in this tissue, MTM-6 is required to maintain low levels of PI(3)P at the plasma membrane. Although we do observe a severe disorganization of PI(3)P in coelomocytes, we do not observe PI(3)P at the plasma membrane of coelomocytes in mtm-6 and mtm-9 mutants. This is probably due to some functional redundancy among the myotubularins in coelomocytes and/or because of differences in the endocytic pathways used by these two tissues. Previous studies on the role of myotubularins in regulating membrane-associated PI(3)P levels relied on the overexpression of MTM1 and MTMR2 in mammalian COS cells and yielded conflicting results (Kim et al., 2002
; Laporte et al., 2002a
).
In coelomocytes, PI(3)P levels do not simply increase in the absence of MTM-6 or MTM-9; rather, PI(3)P becomes disorganized. We believe this is due to the involvement of other myotubularins in coelomocytes, such that in the absence of MTM-6 or MTM-9, there is misregulation rather than simple reduction of phosphatase activity. Furthermore, FYVE domains are known to bind to PI(3)P. We could not genetically analyze the requirement for the MTM-6 FYVE domain in the wild-type protein because overexpression of the MTM-6
FYVE displayed similar cytoplasmic localization and rescue of mtm-6 mutants as MTM-6. However, although overexpressed MTM-6(C335S) localized to membranes and inhibited endocytosis by coelomocytes, these effects were absent if the FYVE domain was reduced. This suggests that the FYVE domain is required for continued localization to membranes and that its function is probably critical for the function of the endogenous protein, that is, under conditions when the protein is not overexpressed.
MTM-6(C335S) and MTM-9 colocalize with ARF-6 and with RME-1. In the absence of a mutation in C. elegans ARF-6, we tried to lower ARF-6 levels in coelomocytes through RNAi. We were unsuccessful because we could not detect any changes in the levels of ARF-6::GFP expressed in these cells after RNAi (Fares, unpublished data). However, RME-1 is required for endocytosis by coelomocytes, and we showed that the colocalization of MTM-6(C335S) with RME-1 is significant because the elimination of RME-1 function in these cells disrupted the membrane association of MTM-6(C335S).
Our conclusion that MTM-6, and probably other myotubularins, functions in ARF-6/RME-1mediated endocytosis helps explain two previous observations. 1) Human MTM1, MTMR2, MTMR3, and MTMR9 localize, in part, to Rac1-induced membrane ruffles (Laporte et al., 2002a
,b
; Nandurkar et al., 2003
), sites of clathrin-independent endocytosis. Interestingly, Arf6 colocalizes with Rac1 and can influence its ability to effect plasma membrane remodeling (Radhakrishna et al., 1999
; Boshans et al., 2000
). Furthermore, Rme1/Ehd1/Pincher associates with membrane ruffles in PC12 cells to regulate a clathrin-independent endocytic pathway (Shao et al., 2002
). 2) Overexpression of Gas3/PMP22, a component of the compact peripheral myelin, results in a peripheral neuropathy, Charcot-Marie-Tooth type 1A, which like type 4B, is characterized by myelination abnormalities, although other pathological details differ among the two diseases. It has recently been shown that overexpressed Gas3/PMP22 specifically affects Arf6 membrane trafficking and that some of the endocytosed Gas3/PMP22 localizes to Arf6 compartments (Chies et al., 2003
).
Links between Arf6 and phosphoinositides are also known. Arf6 regulates phosphatidylinositol 4,5-bisphosphate levels at the plasma membrane and in endosomes (Brown et al., 2001
), and PI(3)P is required to transport endocytosed material from Arf6-endosomes to classic Rab5-labeled early endosomes (Naslavsky et al., 2003
). Myotubularins most likely regulate PI(3)P (and probably other forms of PI) in endosomal compartments, including Arf6-endosomes. Furthermore, given the association of myotubularins with the plasma membrane in mammalian cells and in worms, they could also act to reduce PI(3)P levels at the plasma membrane that may interfere with the initial steps of endocytosis.
We propose that similar disruptions in an Arf6 pathway is at least a partial cause for the development of diseases stemming from mutations in human myotubularins. This and future studies will allow us to better probe the molecular basis for myotubular myopathy and Charcot-Marie-Tooth type 4B and will give us a better understanding of the process of endocytosis in general.
| ACKNOWLEDGMENTS |
|---|
|
|
|---|
| Footnotes |
|---|
Abbreviations used: Arf6, adenosine diphosphate-ribosylation factor 6; GFRP, green fluorescent protein; mRFP1, monomeric red fluorescent protein; PI, phosphoinositide; PI(3)P, phosphoinositide 3-phosphate; RNAi, RNA-mediated interference; BSA-Rhod, bovine serum albumin conjugated to rhodamine.
Online version of this article contains supplementary material for some figures. Online version is available at www.molbiolcell.org. ![]()
Corresponding author. E-mail address: fares{at}email.arizona.edu.
| REFERENCES |
|---|
|
|
|---|
Blondeau, F., Laporte, J., Bodin, S., Superti-Furga, G., Payrastre, B., and Mandel, J.L. (2000). Myotubularin, a phosphatase deficient in myotubular myopathy, acts on phosphatidylinositol 3-kinase and phosphatidylinositol 3-phosphate pathway. Hum. Mol. Genet. 9, 22232229.
Bolino, A., et al. (2000). Charcot-Marie-Tooth type 4B is caused by mutations in the gene encoding myotubularin-related protein-2. Nat. Genet. 25, 1719.[CrossRef][Medline]
Boshans, R.L., Szanto, S., van Aelst, L., and D'Souza-Schorey, C. (2000). ADP-ribosylation factor 6 regulates actin cytoskeleton remodeling in coordination with Rac1 and RhoA. Mol. Cell. Biol. 20, 36853694.
Brenner, S. (1974). The genetics of Caenorhabditis elegans. Genetics 77, 7194.
Brown, F.D., Rozelle, A.L., Yin, H.L., Balla, T., and Donaldson, J.G. (2001). Phosphatidylinositol 4,5-bisphosphate and Arf6-regulated membrane traffic. J. Cell Biol. 154, 10071017.
Campbell, R.E., Tour, O., Palmer, A.E., Steinbach, P.A., Baird, G.S., Zacharias, D.A., and Tsien, R.Y. (2002). A monomeric red fluorescent protein. Proc. Natl. Acad. Sci. USA 99, 78777882.
Caplan, S., Naslavsky, N., Hartnell, L.M., Lodge, R., Polishchuk, R.S., Donaldson, J.G., and Bonifacino, J.S. (2002). A tubular EHD1-containing compartment involved in the recycling of major histocompatibility complex class I molecules to the plasma membrane. EMBO J. 21, 25572567.[CrossRef][Medline]
Chalfie, M., Tu, Y., Euskirchen, G., Ward, W.W., and Prasher, D.C. (1994). Green fluorescent protein as a marker for gene expression. Science 263, 802805.
Chies, R., Nobbio, L., Edomi, P., Schenone, A., Schneider, C., and Brancolini, C. (2003). Alterations in the Arf6-regulated plasma membrane endosomal recycling pathway in cells overexpressing the tetraspan protein Gas3/PMP22. J. Cell Sci. 116, 987999.
Doerks, T., Strauss, M., Brendel, M., and Bork, P. (2000). GRAM, a novel domain in glucosyltransferases, myotubularins and other putative membrane-associated proteins. Trends Biochem. Sci. 25, 483485.[CrossRef][Medline]
Fares, H., and Greenwald, I. (2001a). Genetic analysis of endocytosis in Caenorhabditis elegans: coelomocyte uptake defective mutants. Genetics 159, 133145.
Fares, H., and Greenwald, I. (2001b). Regulation of endocytosis by CUP-5, the Caenorhabditis elegans mucolipin-1 homolog. Nat. Genet. 28, 6468.[CrossRef][Medline]
Fire, A., Xu, S., Montgomery, M.K., Kostas, S.A., Driver, S.E., and Mello, C.C. (1998). Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 391, 806811.[CrossRef][Medline]
Flint, A.J., Tiganis, T., Barford, D., and Tonks, N.K. (1997). Development of "substrate-trapping" mutants to identify physiological substrates of protein tyrosine phosphatases. Proc. Natl. Acad. Sci. USA 94, 16801685.
Gillooly, D.J., Morrow, I.C., Lindsay, M., Gould, R., Bryant, N.J., Gaullier, J.M., Parton, R.G., and Stenmark, H. (2000). Localization of phosphatidylinositol 3-phosphate in yeast and mammalian cells. EMBO J. 19, 45774588.[CrossRef][Medline]
Grant, B., Zhang, Y., Paupard, M.C., Lin, S.X., Hall, D.H., and Hirsh, D. (2001). Evidence that RME-1, a conserved C. elegans EH-domain protein, functions in endocytic recycling. Nat. Cell Biol. 3, 573579.[CrossRef][Medline]
Kim, S.A., Taylor, G.S., Torgersen, K.M., and Dixon, J.E. (2002). Myotubularin and MTMR2, phosphatidylinositol 3-phosphatases mutated in myotubular myopathy and type 4B Charcot-Marie-Tooth disease. J. Biol. Chem. 277, 45264531.
Kim, S.A., Vacratsis, P.O., Firestein, R., Cleary, M.L., and Dixon, J.E. (2003). Regulation of myotubularin-related (MTMR)2 phosphatidylinositol phosphatase by MTMR5, a catalytically inactive phosphatase. Proc. Natl. Acad. Sci. USA 100, 44924497.
Laporte, J., Blondeau, F., Buj-Bello, A., and Mandel, J.L. (2001). The myotubularin family: from genetic disease to phosphoinositide metabolism. Trends Genet. 17, 221228.[CrossRef][Medline]
Laporte, J., Blondeau, F., Gansmuller, A., Lutz, Y., Vonesch, J.L., and Mandel, J.L. (2002a). The PtdIns3P phosphatase myotubularin is a cytoplasmic protein that also localizes to Rac1-inducible plasma membrane ruffles. J. Cell Sci. 115, 31053117.
Laporte, J., Hu, L.J., Kretz, C., Mandel, J.L., Kioschis, P., Coy, J.F., Klauck, S.M., Poustka, A., and Dahl, N. (1996). A gene mutated in X-linked myotubular myopathy defines a new putative tyrosine phosphatase family conserved in yeast. Nat. Genet. 13, 175182.[CrossRef][Medline]
Laporte, J., Liaubet, L., Blondeau, F., Tronchere, H., Mandel, J.L., and Payrastre, B. (2002b). Functional redundancy in the myotubularin family. Biochem. Biophys. Res. Commun. 291, 305312.[CrossRef][Medline]
Lin, S.X., Grant, B., Hirsh, D., and Maxfield, F.R. (2001). Rme-1 regulates the distribution and function of the endocytic recycling compartment in mammalian cells. Nat. Cell Biol. 3, 567572.[CrossRef][Medline]
Mello, C., and Fire, A. (1995). DNA transformation. Methods Cell Biol. 48, 451482.[Medline]
Mochizuki, Y., and Majerus, P.W. (2003). Characterization of myotubularin-related protein 7 and its binding partner, myotubularin-related protein 9. Proc. Natl. Acad. Sci. USA 100, 97689773.
Nandurkar, H.H., Layton, M., Laporte, J., Selan, C., Corcoran, L., Caldwell, K.K., Mochizuki, Y., Majerus, P.W., and Mitchell, C.A. (2003). Identification of myotubularin as the lipid phosphatase catalytic subunit associated with the 3-phosphatase adapter protein, 3-PAP. Proc. Natl. Acad. Sci. USA 100, 86608665.
Naslavsky, N., Weigert, R., and Donaldson, J.G. (2003). Convergence of nonclathrin- and clathrin-derived endosomes involves Arf6 Inactivation and changes in phosphoinositides. Mol. Biol. Cell 14, 417431.
Radhakrishna, H., Al-Awar, O., Khachikian, Z., and Donaldson, J.G. (1999). ARF6 requirement for Rac ruffling suggests a role for membrane trafficking in cortical actin rearrangements. J. Cell Sci. 112, 855866.[Abstract]
Sambrook, J., Fritch, E.F., and Maniatis, T. (1989). Molecular Cloning: A Laboratory Manual, 2nd ed. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press.
Schaletzky, J., Dove, S.K., Short, B., Lorenzo, O., Clague, M.J., and Barr, F.A. (2003). Phosphatidylinositol-5-phosphate activation and conserved substrate specificity of the myotubularin phosphatidylinositol 3-phosphatases. Curr. Biol. 13, 504509.[CrossRef][Medline]
Senderek, J., Bergmann, C., Weber, S., Ketelsen, U.P., Schorle, H., Rudnik-Schoneborn, S., Buttner, R., Buchheim, E., and Zerres, K. (2003). Mutation of the SBF2 gene, encoding a novel member of the myotubularin family, in Charcot-Marie-Tooth neuropathy type 4B2/11p15. Hum. Mol. Genet. 12, 349356.
Shao, Y., Akmentin, W., Toledo-Aral, J.J., Rosenbaum, J., Valdez, G., Cabot, J.B., Hilbush, B.S., and Halegoua, S. (2002). Pincher, a pinocytic chaperone for nerve growth factor/TrkA signaling endosomes. J. Cell Biol. 157, 679691.
Taylor, G.S., Maehama, T., and Dixon, J.E. (2000). myotubularin, a protein tyrosine phosphatase mutated in myotubular myopathy, dephosphorylates the lipid second messenger, phosphatidylinositol 3-phosphate. Proc. Natl. Acad. Sci. USA 97, 89108915.
Walker, D.M., Urbe, S., Dove, S.K., Tenza, D., Raposo, G., and Clague, M.J. (2001). Characterization of MTMR3. an inositol lipid 3-phosphatase with novel substrate specificity. Curr. Biol. 11, 16001605.[CrossRef][Medline]
Wishart, M.J., Taylor, G.S., Slama, J.T., and Dixon, J.E. (2001). PTEN and myotubularin phosphoinositide phosphatases: bringing bioinformatics to the lab bench. Curr. Opin. Cell Biol. 13, 172181.[CrossRef][Medline]
Xue, Y., Fares, H., Grant, B., Li, Z., Clark, S.G., and Skolnik, E.Y. (2003). Genetic analysis of the myotubularin family of phosphatases in Caenorhabditis elegans. J. Biol. Chem. 278, 3438034386.
Zhang, Y., Grant, B., and Hirsh, D. (2001). RME-8, a conserved J-domain protein, is required for endocytosis in Caenorhabditis elegans. Mol. Biol. Cell 12, 20112021.
Zhao, R., Qi, Y., Chen, J., and Zhao, Z.J. (2001). FYVE-DSP2, a FYVE domain-containing dual specificity protein phosphatase that dephosphorylates phosphotidylinositol 3-phosphate. Exp. Cell Res. 265, 329338.[CrossRef][Medline]
This article has been cited by other articles:
![]() |
F. L. Robinson, I. R. Niesman, K. K. Beiswenger, and J. E. Dixon Loss of the inactive myotubularin-related phosphatase Mtmr13 leads to a Charcot-Marie-Tooth 4B2-like peripheral neuropathy in mice PNAS, March 25, 2008; 105(12): 4916 - 4921. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Choudhury, S. Srivastava, Z. Li, K. Ko, M. Albaqumi, K. Narayan, W. A. Coetzee, M. A. Lemmon, and E. Y. Skolnik Specificity of the Myotubularin Family of Phosphatidylinositol-3-phosphatase Is Determined by the PH/GRAM Domain J. Biol. Chem., October 20, 2006; 281(42): 31762 - 31769. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Srivastava, K. Ko, P. Choudhury, Z. Li, A. K. Johnson, V. Nadkarni, D. Unutmaz, W. A. Coetzee, and E. Y. Skolnik Phosphatidylinositol-3 Phosphatase Myotubularin-Related Protein 6 Negatively Regulates CD4 T Cells Mol. Cell. Biol., August 1, 2006; 26(15): 5595 - 5602. [Abstract] [Full Text] [PDF] |
||||
![]() |
O. Lorenzo, S. Urbe, and M. J. Clague Systematic analysis of myotubularins: heteromeric interactions, subcellular localisation and endosomerelated functions J. Cell Sci., July 15, 2006; 119(14): 2953 - 2959. [Abstract] [Full Text] [PDF] |
||||
![]() |
A.-S. Nicot, H. Fares, B. Payrastre, A. D. Chisholm, M. Labouesse, and J. Laporte The Phosphoinositide Kinase PIKfyve/Fab1p Regulates Terminal Lysosome Maturation in Caenorhabditis elegans Mol. Biol. Cell, July 1, 2006; 17(7): 3062 - 3074. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Bonneick, M. Boentert, P. Berger, S. Atanasoski, N. Mantei, C. Wessig, K. V. Toyka, P. Young, and U. Suter An animal model for Charcot-Marie-Tooth disease type 4B1 Hum. Mol. Genet., December 1, 2005; 14(23): 3685 - 3695. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. L. Robinson and J. E. Dixon The Phosphoinositide-3-phosphatase MTMR2 Associates with MTMR13, a Membrane-associated Pseudophosphatase Also Mutated in Type 4B Charcot-Marie-Tooth Disease J. Biol. Chem., September 9, 2005; 280(36): 31699 - 31707. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. J. Hermann, L. K. Schroeder, C. A. Hieb, A. M. Kershner, B. M. Rabbitts, P. Fonarev, B. D. Grant, and J. R. Priess Genetic Analysis of Lysosomal Trafficking in Caenorhabditis elegans Mol. Biol. Cell, July 1, 2005; 16(7): 3273 - 3288. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Srivastava, Z. Li, L. Lin, G. Liu, K. Ko, W. A. Coetzee, and E. Y. Skolnik The Phosphatidylinositol 3-Phosphate Phosphatase Myotubularin- Related Protein 6 (MTMR6) Is a Negative Regulator of the Ca2+-Activated K+ Channel KCa3.1 Mol. Cell. Biol., May 1, 2005; 25(9): 3630 - 3638. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Bolino, A. Bolis, S. C. Previtali, G. Dina, S. Bussini, G. Dati, S. Amadio, U. Del Carro, D. D. Mruk, M. L. Feltri, et al. Disruption of Mtmr2 produces CMT4B1-like neuropathy with myelin outfolding and impaired spermatogenesis J. Cell Biol., November 22, 2004; 167(4): 711 - 721. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. A. Smith, S. E. Dho, J. Donaldson, U. Tepass, and C. J. McGlade The Cell Fate Determinant Numb Interacts with EHD/Rme-1 Family Proteins and Has a Role in Endocytic Recycling Mol. Biol. Cell, August 1, 2004; 15(8): 3698 - 3708. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||